Atara Biotherapeutics Inc
ATRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$75.51M
Close$
$-2.33
126.1% downside
Current Fair Value
126.1% downsideOvervalued by 126.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $75.51 Million |
|---|---|
| Enterprise Value | $76.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.61 |
| Beta | 0.09 |
| Outstanding Shares | 14,081,000 |
Return
| Return on Equity | 25.37% |
|---|---|
| Return on Assets | -47.34% |
| Return on Invested Capital | -50.80% |
Valuation & Multiples
| P/E Ratio | -12.7 |
|---|---|
| PEG | 11.45 |
| Price to Sales | 8.91 |
| Price to Book Ratio | -2.97 |
| Enterprise Value to Revenue | 3.91 |
| Enterprise Value to EBIT | -10.55 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | -0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$2.90 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$550,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 18.20% |
|---|---|
| Total Invested | $19,490▼ 99.84% |
| Investors Holding | 3▼ 31.00% |
ESG Score
No data
About Atara Biotherapeutics Inc
CEO: Pascal Touchon